May 5, 2026 — Leads & Copy — Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW), a clinical-stage biopharmaceutical company focused on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies for cancer and autoimmune diseases, has announced its CEO and CFO will attend the D. Boral Capital 2026 Global Conference for one-on-one investor meetings.
The conference, hosted by D. Boral Capital, is scheduled for May 7, 2026, at The Plaza Hotel in New York, NY. This forum is designed to connect executives from emerging-growth public and private companies with institutional investors and strategic partners.
Interested investors can schedule meetings by contacting their D. Boral Capital representative.
Estrella Immunopharma is dedicated to developing ARTEMIS T-cell therapies targeting CD19 and CD22 to treat cancers and autoimmune diseases. The company’s lead product candidate, EB103, targets CD19, a protein found on almost all B-cell leukemias and lymphomas, utilizing Eureka’s ARTEMIS technology. Estrella is also developing EB104, which targets both CD19 and CD22, another protein expressed on most B-cell malignancies.
For more information about Estrella Immunopharma, visit www.estrellabio.com.
Source: Estrella Immunopharma, Inc.
